Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Memantine (compound)


PubChem
Name: Memantine
PubChem Compound ID: 11229655
Description: AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
Molecular formula: C12H22ClN
Molecular weight: 215.763 g/mol
DrugBank
Identification
Name: Memantine
Name (isomeric): DB01043
Drug Type: small molecule
Description: AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
Synonyms:
Memantine [INN]; Memantinum [INN-Latin]; DMAA; Memantine HCL; Memantina [INN-Spanish]; Memantine Hydrochloride
Brand: Namenda, Ebixa
Category: Antidyskinetics, Antiparkinson Agents, Dopamine Agents, Central Nervous System Agents, Excitatory Amino Acid Antagonists
CAS number: 19982-08-2
Pharmacology
Indication: For the treatment of moderate to severe dementia of the Alzheimer's type.
Pharmacology:
Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal exc...
show more »
Mechanism of Action:
Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca<...
show more »
Absorption: Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
Protein binding: 45%
Biotransformation: Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane.
Route of elimination: Memantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. It is excreted predominantly in the urine, unchanged.
Half Life: 60-100 hours
Toxicity: Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Take without regard to meals.
Drug interaction:
Sodium bicarbonatePossible increased levels of memantine
DichlorphenamidePossible increased levels of memantine
AmantadineIncreased risk of CNS adverse effects with this association
KetamineIncreased risk of CNS adverse effects with this association
MethazolamidePossible increased levels of memantine
show more »

Targets


Enzymes


Transporters